anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Medicament comprises at least one insulin and at least one glucagon-like peptide-1 (GLP-1) agonist. The medicament is formulated and/or confectioned in such a manner that it contains the insulin and GLP-1 agonist in a predetermined amount and is administered in an amount with respect to the need of a patient. Independent claims are also included for: (1) a kit comprising the medicament; (2) a combination of Gly(A21)-Arg(B31)-Arg(B32)-human insulin and desPro 3> 6>-exendin-4(1-39)-Lys 6-NH 2 and/or their salts; (3) treating a patient with the medicament or the kit, comprising (a) selecting a dose of at least one insulin, (b) selecting a dose of at least one GLP-1-agonist, (c) selecting a composition from the first, second and optionally the further composition of the medicaments, which contain the dose of (a) and (b) in a concentration, so that the doses of (a) and (b) are present in same volumes and (d) determining and administering an amount, which corresponds to the doses of (a) and (b); and (4) producing the medicament comprising formulating and/or confectioning so that it contains the insulin and the GLP-1 agonist in a predetermined amount and administering in an amount with respect to the need of a patient; and (5) a device comprising the composition or the kit, where the device contains the pharmaceutical composition of the medicament in separate containers and allows the dosing of the pharmaceutical composition independently from one another. ACTIVITY : Antidiabetic; Anorectic. Test details are described but no results given. MECHANISM OF ACTION : Glucagon-like peptide-1 agonist.
PURPOSE OF REVIEW: The purpose of this article is to present recent findings of KU002 (brimapitide) as a novel treatment option for interstitial cystitis/bladder pain syndrome (IC/BPS).
RECENT FINDINGS: IC/BPS is a complex and poorly understood heterogeneous syndrome, with many burdensome symptoms that severely affect patients' quality of life. Treatment options beyond conservative and nonpharmacologic approaches remain limited, and there is an unmet medical need for effective medical treatments. While there are multiple ongoing clinical trials in this area, only a few explore new treatment options. This article summarizes current ongoing development and reports the findings of one such trial.
SUMMARY: In a phase 1/2a exploratory trial, intravesical instillation of brimapitide confirmed local action while eliciting in minimal systemic exposure, resulting in a promising and favorable safety profile. Efficacy exploration suggests that brimapitide reduces pain, improves signs and symptoms of IC/BPS and improves the general wellbeing of the study participants.
PROBLEM TO BE SOLVED: To provide an antibody for factor xa inhibitor and method for using the same.SOLUTION: One of the major limitations of anticoagulant therapy is the limitation of the ability to rapidly reverse anticoagulant activity in the case of treatment-related bleeding risk and in cases of overdosage or required emergency surgical intervention. Therefore, a specific effective antidote for all forms of anticoagulant therapy is highly desirable. The present invention relates to an antidote to an anticoagulant that targets factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives described herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.SELECTED DRAWING: None
Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
PURPOSE:To provide a low-cost, high-safety title composition free from physiologically active compound, by adding a buffer solution containing malic acid, to a carpronium chloride composition. CONSTITUTION:The pH of a carpronium composition (e.g. hair lotion, hair cream, etc.) is adjusted between about 4 and 6 by adding a buffer solution containing malic acid (e.g. sodium malate-malic acid buffer solution). The residual amount of the carpronium chloride in the above prepared composition is more than about 90% after 3-year storage at room temperature.
In a 104-week carcinogenicity study in rats, parathyroid hormone was given subcutaneously at doses of 10, 50 and 150 mcg/kg/day. These doses resulted in systemic exposures that were, respectively 3 to 71 times higher than systemic exposure observed in humans following a subcutaneous dose of 100 mcg/day based on AUC. Systemic exposure at the 10 mcg/kg/day dose of parathyroid hormone was 3-5 times greater AUC than the exposure observed in hypoparathyroidism subjects at the clinical dose of 100 mcg/day. This is the lowest dose at which a parathyroid hormone-related increase in bone tumors was observed in rats. Higher exposures resulted in a marked dose-related increase in all bone tumors including osteoma, osteoblastoma and osteosarcomas in both sexes. The bone tumors in rats occurred in association with a large increase in bone mass and focal osteoblast hyperplasia. However, since bone metabolism in the rat differs from that in humans, the relevance of these animal findings to humans is uncertain.

Parathyroid hormone is not genotoxic in any of the following test systems: the bacterial reverse mutation (Ames) assay or the in vitro mammalian cell forward-gene mutation (AS52/XPRT) assay study with and without metabolic activation.

No effect on fertility was observed in male and female rats given parathyroid hormone at doses up to 1000 mcg/kg/day (120 times systemic exposure after a clinical dose of 100 mcg/day).
The invention relates to Fc receptor binding proteins. The technical field of the present application relates to proteins that bind Fc receptors. Inhibition of IgG binding to FcRn negatively alters IgG serum half-life by preventing IgG recycling. Preventing IgG recycling may have many therapeutic applications. Accordingly, antibodies that bind FcRn and methods of using these antibodies are disclosed. In one embodiment, there is provided a method of detecting FcRn in a subject, the method comprising: administering an anti-FcRn antibody to a subject and, if present, detecting an interaction between the antibody and the FcRn. anti-FcRn antibodies are characterized by a C in DX2504 antibodies H At least one of a cysteine mutation and/or a C-terminal lysine deletion in the domain.
The present invention provides a peptide having anti-inflammatory and bone differentiation promoting activities, which comprises one amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID Nos. 1, 2 and 3. The present invention provides a peptide having hair growth promoting activity, which comprises one amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID Nos. 1 and 2. The peptide consisting of the amino acid sequence of seq id No. 1, 2 or 3 of the present invention inhibits the expression of inflammatory cytokines and inhibits the proliferation of inflammatory cells, resulting in the development of anti-inflammatory activity, and also increases the phosphorylation of PI3K, smad, smad5 and Smad8 involved in bone formation, and increases the expression of ALP, OPG and BSP, resulting in the promotion of bone differentiation. The peptide consisting of the amino acid sequence of sequence 1 or 2 of the present invention promotes the proliferation of hair follicle cells and umbilical vein endothelial cells, increases the phosphorylation of ERK, increases the expression of PI3K, β -catenin, IGF-1, KGF, and Wnt3a, which are proteins involved in hair growth, and decreases the expression of DKK-1, which is a hair loss gene, thereby exhibiting effects of preventing hair loss and promoting hair growth.
Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
BACKGROUND AND OBJECTIVES: The learning healthcare system (LHS) has been developed to integrate patients' clinical data into clinical decisions and improve treatment outcomes. Having little guidance on this integration process, we aim to explain (a) an applicable analytic tool for clinicians to evaluate the clinical outcomes at a group and an individual level and (b) our quality improvement (QI) project, analyzing the outcomes of a new outpatient pain rehabilitation program ("Back-in-Action": BIA) and applying the analysis results to modify our clinical practice.
METHODS: Through our LHS (CHOIR; https://choir.stanford.edu), we administered the Pain Catastrophizing Scale (PCS), Chronic Pain Acceptance Questionnaire (CPAQ), and Patient-Reported Outcomes Measures (PROMIS)® before and after BIA. After searching for appropriate analytic tools, we decided to use the Reliable Change Index (RCI) to determine if an observed change in the direction of better (improvement) or worse (deterioration) would be beyond or within the measurement error (no change).
RESULTS: Our RCI calculations revealed that at least a 9-point decrease in the PCS scores and 10-point increase in the CPAQ scores would indicate reliable improvement. RCIs for the PROMIS measures ranged from 5 to 8 T-score points (i.e., 0.5-0.8 SD). When evaluating change scores of the PCS, CPAQ, and PROMIS measures, we found that 94% of patients showed improvement in at least one domain after BIA and 6% showed no reliable improvement.
CONCLUSIONS: Our QI project revealed RCI as a useful tool to evaluate treatment outcomes at a group and an individual level, and RCI could be incorporated into the LHS to generate a progress report automatically for clinicians. We further explained how clinicians could use RCI results to modify a clinical practice, to improve the outcomes of a pain program, and to develop individualized care plans. Lastly, we suggested future research areas to improve the LHS application in pain practice.
This study aims to evaluate the cost-efficacy and applicability of the treatment of lesions moderate caries using sealants as an alternative to the restorations on occlusal surfaces of deciduous teeth. 96 children aged 3-6 years will be selected. Children must have at least one occlusal surface classified as scores 3 or 4 of International Caries Detection and Assessment System (ICDAS). Children will be randomly allocated according to the treatment: glass ionomer sealant and restoration with glass ionomer. After treatment, teeth will be assessed clinically after 6, 12, 18 and 24 months by trained and blinded examiners regarding the treatment received. The need of reintervention initially treated, either by failures that require repeating of the same procedure or for progression of caries lesions will be considered as primary outcomes. The secondary outcomes will be the chil's acceptability to the treatment.
Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
The primary goal of this study is to evaluate the efficacy of Enbrel in patients with primary systemic amyloidosis using a one-stage, phase II study design with an interim analysis. This study will also assess survival and progression times, symptom relief, and toxicity associated with Enbrel in primary systemic amyloidosis patients. Two groups of patients with very different risk profiles can be identified with respect to this disease. Patients with symptomatic cardiac disease and/or at least two involved organs ar at high risk and historically have a median survival less than six months. Patients without these conditions have a significantly better prognosis. Both subgroups will be studied in the present study, and essentially two phase-II clinical trials, one for each subgroup, will be run in parallel.
Preeclampsia is a multisystem disorder associated with defective trophoblast invasion, maternal syndrome, and capillary endothelial leak. The presence of ascites/third space fluid accumulation increases the risk of maternal morbidity and mortality. The current criteria/guidelines of preeclampsia do not establish the presence of ascites as a marker of severity or recognize the timing and need for early delivery despite associated complications. Medline and Embase databases were searched to identify relevant literature, reported up to December 2023, regarding the pathophysiology, pregnancy outcome, and management of preeclampsia complicated with ascites. A total of 5 studies on pathophysiology and eight on pregnancy outcomes met the inclusion criteria, with 41 case reports on ascites in preeclampsia. The etiopathogenesis for the development of ascites in preeclampsia includes endothelial damage, capillary hyperpermeability, release of vasoconstrictive agents, reduced intravascular oncotic pressure, and raised intraabdominal pressure. The presence of ascites represents the extreme form of microvascular damage, which also correlates with the raised sFlt-1 levels in this condition. The adverse pregnancy outcomes include increased risk of congestive heart failure, eclampsia, renal failure, disseminated intravascular coagulation, acute respiratory distress syndrome, and maternal death. The presence of ascites in preeclampsia is associated with the deterioration of the maternal condition. Hence, it is indicative of preeclampsia with severe features and requires vigilant monitoring, and prompt delivery may be considered.
Objective: To investigate the clinical and pathologic features and diagnosis of follicular lymphoma (FL) with a predominantly diffuse growth pattern (DFL) with 1p36 deletion. Methods: Eight cases of DFL with 1p36 deletion diagnosed at Department of Pathology, Beijing Friendship Hospital, Capital Medical University (n=5) and the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital (n=3) from January 2017 to January 2023 were included. Their clinicopathologic features and follow-up data were analyzed. Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed. Results: There were five males and three females, with a median age of 67 years, and inguinal lymphadenopathy was found as the main symptom. Histologically, similar morphologic features were sheared among all cases, with effaced nodal structure and characterized by proliferation of centrocytes in a diffuse pattern, with or without follicular components. The germinal center-related markers such as CD10 and/or bcl-6 were expressed in the tumor cells, and 1p36 deletion but not bcl-2 translocation was appreciable in these cases. Conclusions: DFL with 1p36 deletion is a rare subtype of FL, with some overlaps with other types of FL or indolent B-cell lymphomas in their pathologic features. An accurate diagnosis requires comprehensive considerations based on their clinical, pathologic, immunohistochemical, and molecular features.
To measure the benefit of cysteinyl leukotriene blockade in favourably altering the pathophysiology of coronary artery disease. We hypothesize that patients admitted to hospital with acute coronary syndromes will have markedly abnormal endothelial function as measured by peripheral vasomotor responses to forearm ischemia. Patients with myocardial infarction and unstable angina have markedly increased renal excretion of the cysteinyl leukotriene metabolite LTE4 as observed in patients with asthma. Observations that coronary vessel tone is negatively affected by leukotrienes C4,D4 and E4 which influences the atherosclerotic process in these arteries. Studies that isolated the epicardial coronary arteries and challenged the vessels with an LTC4 and LTD4 concentration showed that coronary arterial myocytes were found to produce cysteinyl leukotrienes which lead to responsive vasoconstriction. The continued stimulus of vasoconstriction over time leads to endothelial dysfunction and disruption of the endothelium integrity which then leads to stressors that encourage a disease state and atherosclerosis.In this study we will specifically assess peripheral endothelial function by measuring brachial artery diameter changes and PAT responses to temporary forearm ischemia in patients that have had an acute coronary event before and after receiving Montelukast. As well we will measure leukotriene assays both in blood and urine .
Participants will consume 1 portion (\~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
PROBLEM TO BE SOLVED: To efficiently mass produce only a mature type dimer from a precursor of bone inducing factor having various molecular weights produced by animal cells by recombinant DNA technology using a specific enzyme. SOLUTION: Dimers of precursor of bone inducing factor having various molecular weights are treated with a processing enzyme. Especially an expression vector of the bone inducing factor precursor and an expression vector of a processing vector are transduced into an animal cell strain, and the cell strain is cultured to produce a mature type bone inducing factor, which is isolated from the culture solution. Mature type MP52, BMP-2, BMP-4, BMP-6 or BMP-7 is preferable as the mature type bone inducing factor. Furin is preferable as the processing enzyme. A DNA base sequence coding the whole amino acid sequence of furin is used as a cDNA coding furin and preferably a DNA base sequence coding a secretion type variant is used. The mature type bone inducing factor is useful for treating and preventing damage of bone, cartilage or tooth and is applicable to an artificial root of a tooth.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to a pharmaceutical composition for oral administration. The composition comprises a carrier and dopamine agonist as an active component. The composition is presented as quickly dispersing medicinal form designating for rapid release of an active component in the mouth cavity. Invention proposes also compositions that comprise additionally an antiemetic agent and/or opioide antagonist. Except for, the invention proposes a process for preparing such compositions, the use of such compositions for treatment and/or estimation of Parkinson's disease development and therapeutic products and sets for administration of dopamine agonist and combined administration of dopamine agonist and an antiemetic agent and/or opioide antagonist. Invention provides decrease of undesirable peripheral effects. EFFECT: improved properties of compositions. 26 cl, 2 dwg, 17 tbl
Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
Adverse reaction information concerning albuterol sulfate inhalation aerosol is derived from a 12-week, double-blind, double-dummy study which compared albuterol sulfate inhalation aerosol, a CFC 11/12 propelled albuterol inhaler, and an HFA-134a placebo inhaler in 565 asthmatic patients. The following table lists the incidence of all adverse events (whether considered by the investigator drug related or unrelated to drug) from this study which occurred at a rate of 3% or greater in the albuterol sulfate inhalation aerosol treatment group and more frequently in the albuterol sulfate inhalation aerosol treatment group than in the placebo group. Overall, the incidence and nature of the adverse reactions reported for albuterol sulfate inhalation aerosol and a CFC 11/12 propelled albuterol inhaler were comparable.

Adverse events reported by less than 3% of the patients receiving albuterol sulfate inhalation aerosol, and by a greater proportion of albuterol sulfate inhalation aerosol patients than placebo patients, which have the potential to be related to albuterol sulfate inhalation aerosol include: dysphonia, increased sweating, dry mouth, chest pain, edema, rigors, ataxia, leg cramps, hyperkinesia, eructation, flatulence, tinnitus, diabetes mellitus, anxiety, depression, somnolence, rash. Palpitation and dizziness have also been observed with albuterol sulfate inhalation aerosol.

Adverse events reported in a 4-week pediatric clinical trial comparing albuterol sulfate inhalation aerosol and a CFC 11/12 propelled albuterol inhaler occurred at a low incidence rate and were similar to those seen in the adult trials.

In small, cumulative dose studies, tremor, nervousness, and headache appeared to be dose related.

Rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema have been reported after the use of inhaled albuterol. In addition, albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vertigo, central nervous system stimulation, insomnia, headache, metabolic acidosis, and drying or irritation of the oropharynx.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, \& Steege, 2003).
Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
Iron and zinc deficiency remain a major worldwide public health problem, especially in developing countries such as India. In this randomized study, 700 children aged 12-18 months from Mumbai, Maharashtra, India will be fed either iron and zinc biofortified pearl millet or control pearl millet three times per day, six days per week, for nine months. The goal of this study is to examine the effects of iron and zinc biofortified millet on immune function, growth, and cognitive function in this age group. The key outcome measures are biomarkers of iron and zinc status, growth, and immune function. Serum concentrations of hemoglobin, ferritin, serum transferrin receptor, and zinc will be assessed at enrollment (baseline), at an intermediate time point (midline; random serial sampling) and after 9 months of follow-up (endline). Additionally, we will measure concentrations of C-reactive protein (CRP) and alpha 1-acid glycoprotein (AGP), as iron and zinc biomarkers can be influenced by inflammation. To assess cognitive function in a subset, multiple specific aspects of memory, attention, and processing speed will be assessed. Higher-level, integrative cognitive abilities that require the coordination of multiple specific functions, such as problem-solving and exploratory behavior and global aspects of attention during free play with toys, will also be assessed.